Literature DB >> 1985211

Inhibition of human immunodeficiency virus type 1 replication in human T cells stably expressing antisense RNA.

G Sczakiel1, M Pawlita.   

Abstract

Human T-lymphoid cell lines with constitutive intracellular expression of antisense RNA complementary to a 407-bp sequence of the 5' leader-gag region of human immunodeficiency virus type 1 were established by using a nonretroviral expression vector. In cell lines with antisense RNA expression detectable by Northern (RNA) hybridization, human immunodeficiency virus type 1 replication was inhibited to 88% 10 days postinfection and this inhibition lasted 3 weeks postinfection.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1985211      PMCID： PMC240540     

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  28 in total

1.  Ribozymes as potential anti-HIV-1 therapeutic agents.

Authors:  N Sarver; E M Cantin; P S Chang; J A Zaia; P A Ladne; D A Stephens; J J Rossi
Journal:  Science       Date:  1990-03-09       Impact factor: 47.728

Review 2.  Antisense RNA and DNA.

Authors:  H M Weintraub
Journal:  Sci Am       Date:  1990-01       Impact factor: 2.142

3.  Inhibition of human immunodeficiency virus (HIV-1) replication by synthetic oligo-RNA derivatives.

Authors:  S Shibahara; S Mukai; H Morisawa; H Nakashima; S Kobayashi; N Yamamoto
Journal:  Nucleic Acids Res       Date:  1989-01-11       Impact factor: 16.971

4.  Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide.

Authors:  P C Zamecnik; M L Stephenson
Journal:  Proc Natl Acad Sci U S A       Date:  1978-01       Impact factor: 11.205

5.  Inhibition of human immunodeficiency virus replication in cell culture by endogenously synthesized antisense RNA.

Authors:  A Rhodes; W James
Journal:  J Gen Virol       Date:  1990-09       Impact factor: 3.891

6.  Specific inhibition of human immunodeficiency virus type 1 replication by RNA transcribed in sense and antisense orientation from the 5'-leader/gag region.

Authors:  G Sczakiel; M Pawlita; A Kleinheinz
Journal:  Biochem Biophys Res Commun       Date:  1990-06-15       Impact factor: 3.575

7.  Cloning and functional analysis of multiply spliced mRNA species of human immunodeficiency virus type 1.

Authors:  S Schwartz; B K Felber; D M Benko; E M Fenyö; G N Pavlakis
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

8.  Phosphate-methylated DNA aimed at HIV-1 RNA loops and integrated DNA inhibits viral infectivity.

Authors:  H M Buck; L H Koole; M H van Genderen; L Smit; J L Geelen; S Jurriaans; J Goudsmit
Journal:  Science       Date:  1990-04-13       Impact factor: 47.728

9.  Characterization of EBV-genome negative "null" and "T" cell lines derived from children with acute lymphoblastic leukemia and leukemic transformed non-Hodgkin lymphoma.

Authors:  U Schneider; H U Schwenk; G Bornkamm
Journal:  Int J Cancer       Date:  1977-05-15       Impact factor: 7.396

10.  Inhibition of human immunodeficiency virus type 1-mediated cytopathic effects by poly(L-lysine)-conjugated synthetic antisense oligodeoxyribonucleotides.

Authors:  M Stevenson; P L Iversen
Journal:  J Gen Virol       Date:  1989-10       Impact factor: 5.141
View more
  22 in total

Review 1.  Gene therapy for HIV.

Authors:  A M Lever
Journal:  Sex Transm Infect       Date:  2001-04       Impact factor: 3.519

2.  Effective inhibition of influenza virus production in cultured cells by external guide sequences and ribonuclease P.

Authors:  D Plehn-Dujowich; S Altman
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-23       Impact factor: 11.205

Review 3.  Gene therapy for infectious diseases.

Authors:  B A Bunnell; R A Morgan
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

4.  Membrane-anchored peptide inhibits human immunodeficiency virus entry.

Authors:  M Hildinger; M T Dittmar; P Schult-Dietrich; B Fehse; B S Schnierle; S Thaler; G Stiegler; R Welker; D von Laer
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

5.  Endogenous expression of a high-affinity pseudoknot RNA aptamer suppresses replication of HIV-1.

Authors:  Laurent Chaloin; Maik Jörg Lehmann; Georg Sczakiel; Tobias Restle
Journal:  Nucleic Acids Res       Date:  2002-09-15       Impact factor: 16.971

6.  A nonproducer, interfering human immunodeficiency virus (HIV) type 1 provirus can be transduced through a murine leukemia virus-based retroviral vector: recovery of an anti-HIV mouse/human pseudotype retrovirus.

Authors:  M Federico; F Nappi; G Ferrari; C Chelucci; F Mavilio; P Verani
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

7.  A new antisense tRNA construct for the genetic treatment of human immunodeficiency virus type 1 infection.

Authors:  M A Biasolo; A Radaelli; L Del Pup; E Franchin; C De Giuli-Morghen; G Palu
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

8.  In vitro selection of fast-hybridizing and effective antisense RNAs directed against the human immunodeficiency virus type 1.

Authors:  K Rittner; C Burmester; G Sczakiel
Journal:  Nucleic Acids Res       Date:  1993-03-25       Impact factor: 16.971

9.  Specific inhibition of aphthovirus infection by RNAs transcribed from both the 5' and the 3' noncoding regions.

Authors:  A Gutiérrez; E Martínez-Salas; B Pintado; F Sobrino
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

10.  Comparison of trans-dominant inhibitory mutant human immunodeficiency virus type 1 genes expressed by retroviral vectors in human T lymphocytes.

Authors:  I Bahner; C Zhou; X J Yu; Q L Hao; J C Guatelli; D B Kohn
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.